

Hybrid Medical Preferred Drug List-Commercial

The CVS Caremark® Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The CVS Caremark Medical Preferred Drug List includes the listed products only and any other product may be available under a plan's medical benefit.

The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product.

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Acromegaly	Lanreotide Acetate Signifor LAR Somavert	Sandostatin LAR Somatuline Depot
Alpha-1 Antitrypsin Deficiency	Aralast Glassia Zemaira	Prolastin-C
Autoimmune Infused Infliximab	Infliximab Remicade Renflexis	Avsola Inflectra
Autoimmune Infused Other	Actemra Cimzia Orencia Skyrizi (IV & SC)	Entyvio Ilumya Simponi Aria Stelara
Avastin/Biosimilars (Oncology)	Alymsys Avastin Vegzelma Zirabev	Mvasi

^{*}Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Botulinum Toxins	Myobloc	Botox Dysport Xeomin
Breast Cancer- MAb	Margenza	Enhertu Kadcyla Perjeta Phesgo
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen Mircera Retacrit	Aranesp Procrit
Hemophilia – Factor VIII- Long Acting	Esperoct	Adynovate Eloctate Jivi
Hemophilia- Factor VIII- Recombinant	Recombinate	Advate Afstyla Kogenate Kovaltry Novoeight Nuwiq Xyntha
Hemophilia – Factor IX- Recombinant	Benefix Ixinity Rixubis	Alprolix Idelvion Rebinyn

^{*}Non-preferred product(s) are only available if process exception criteria are met.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Fylnetra Nyvepria Stimufend Udenyca Ziextenzo	Fulphila Neulasta
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Granix Leukine Neupogen Nivestym Releuko	Zarxio
Hereditary Angioedema	Berinert	Ruconest
Hereditary Transthyretin Amyloidosis	Amvuttra Tegsedi	Onpattro
Lysosomal Storage Disorders – Gaucher Disease	Cerezyme VPRIV	Elelyso
Multiple Myeloma Proteasome Inhibitors	Kyprolis	Ninlaro Velcade
Multiple Sclerosis (Infused)	Briumvi Lemtrada	Ocrevus Tysabri
Myasthenia Gravis		Soliris Ultomiris
Osteoarthritis, Viscosupplements – Single Injection	Durolane Gel-One	Monovisc Synvisc-One

^{*}Non-preferred product(s) are only available if process exception criteria are met.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Osteoarthritis, Viscosupplements – Multi Injection	Euflexxa Gelsyn-3 GenVisc 850 Hyalgan Hymovis Supartz FX SynoJoynt Synvisc Triluron TriVisc Visco-3	Orthovisc
Paroxysmal Nocturnal Hemoglobinuria (PNH)	Empaveli	Soliris Ultomiris
Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Agents and Antagonist Agents	Camcevi Firmagon Lupron Depot Trelstar Zoladex	Eligard
Retinal Disorders Agents	Eylea Lucentis Vabysmo	Avastin Byooviz Cimerli
Rituximab	Riabni Rituxan Rituxan Hycela Ruxience	Truxima

^{*}Non-preferred product(s) are only available if process exception criteria are met.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Severe Asthma	Cinqair	Dupixent Fasenra Nucala Tezspire Xolair
Spinal Muscular Atrophy		Zolgensma
Trastuzumab	Herceptin Herceptin Hylecta Ontruzant Trazimera	Herzuma Kanjinti Ogivri

^{*}Non-preferred product(s) are only available if process exception criteria are met.